Search Results - "Marr, Alissa"

A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation by Trinh, Jonathan Q, Banskota, Shristi Upadhyay, Marr, Alissa S

“…Spiradenocarcinomas are rare malignant skin adnexal tumors. We describe a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who…”
Get more information

Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study by Trinh, Jonathan Q, Xiong, Ying, Smith, Lynette M, Abughanimeh, Omar, Marr, Alissa S, Ganti, Apar K

“…The PACIFIC trial demonstrated improved survival in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with durvalumab following…”
Get more information

Association Between Hospital Volume, Therapy Types, and Overall Survival in Stage III and IV Cutaneous Malignant Melanoma by Tella, Sri Harsha, Kommalapati, Anuhya, Ganti, Apar Kishor, Marr, Alissa S

“…The advent of targeted therapies and immunomodulatory agents has revolutionized the management of advanced cutaneous malignant melanoma (MMel) by prolonging…”
Get more information

Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study by Duvivier, Herbert L, Rothe, Michael, Mangat, Pam K, Garrett-Mayer, Elizabeth, Ahn, Eugene R, Al Baghdadi, Tareq, Alva, Ajjai S, Dublis, Stephanie A, Cannon, Timothy L, Calfa, Carmen J, Li, Rui, Behl, Deepti, Chiu, Vi K, Gold, Philip J, Marr, Alissa S, Mileham, Kathryn F, Powell, Steven Francis, Rodon, Jordi, Thota, Ramya, Grantham, Gina N, Gregory, Abigail, Hinshaw, Dominique C, Halabi, Susan, Schilsky, Richard L

“…The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a pragmatic basket trial evaluating antitumor activity of approved targeted agents in…”
Get full text

Management of patients with lung cancer and poor performance status by Gajra, Ajeet, Marr, Alissa S, Ganti, Apar Kishor

“…Patients who are able to care for themselves but are unable to perform most work-related activities are considered to have a poor performance status (PS)…”
Get more information

Early Stage Non–Small-Cell Lung Cancer in Octogenarian and Older Patients: A SEER Database Analysis by Ganti, Apar Kishor, Shostrom, Valerie, Alorabi, Mohamed, Zhen, Weining (Ken), Marr, Alissa S, Trujillo, Karin, Islam, K.M. Monirul, Lackner, Rudy P, Kessinger, Anne

“…Micro-Abstract Evidence guiding the management of octogenarian and older patients with non–small-cell lung cancer is based on data derived from younger…”
Get full text

Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study by Schuetze, Scott, Rothe, Michael, Mangat, Pam K, Garrett-Mayer, Elizabeth, Meric-Bernstam, Funda, Calfa, Carmen J, Farrington, Laura Catherine, Livingston, Michael B, Wentzel, Kristopher, Behl, Deepti, Kier, Yelena, Marr, Alissa S, von Mehren, Margaret, Press, Joshua Z, Thota, Ramya, Grantham, Gina N, Gregory, Abigail, Hinshaw, Dominique C, Halabi, Susan, Schilsky, Richard L

“…Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted…”
Get more information

Predictive ability of Charlson comorbidity index on outcomes from lung cancer by Ganti, Apar Kishor, Siedlik, Emily, Marr, Alissa S, Loberiza, Jr, Fausto R, Kessinger, Anne

“…The effect of age and/or comorbidities on management decisions in lung cancer patients has been debated. The Charlson Comorbidity Index (CCI) was developed to…”
Get full text

Resected small cell lung cancer-what do we do next? by Marr, Alissa S, Ganti, Apar Kishor

Get full text

Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study by Worden, Francis P, Pisick, Evan, Rothe, Michael, Mangat, Pam K, Garrett-Mayer, Elizabeth, Khalil, Maged F, Carrizosa, Daniel R, Bauman, Jessica R, Leidner, Rom S, Duvivier, Herbert L, Fu, Siqing, Park, Min S, Yost, Kathleen J, Calfa, Carmen J, Marr, Alissa S, Balmanoukian, Ani S, Behl, Deepti, Cannon, Timothy L, Nabell, Lisle, Powell, Steven Francis, Thota, Ramya, Hinshaw, Dominique C, Gregory, Abigail, Grantham, Gina N, Halabi, Susan, Schilsky, Richard L

“…Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in…”
Get more information

Resected small cell lung cancer-time for more? by Marr, Alissa S, Zhang, Chi, Ganti, Apar Kishor

“…Small cell lung cancer (SCLC) often presents with either regional or systemic metastases, but approximately 4% of patients present with a solitary pulmonary…”
Get full text

774 NeoPOWER: A phase II study of neoadjuvant PD-1 blockade with cemiplimab in high risk localized, locally recurrent and regionally advanced cutaneous squamous cell carcinoma by In, Gino K, Chandra, Sunandana, Sosman, Jeffrey, Barrett, Erin, Wysong, Ashley, Marr, Alissa, Mammen, Joshua, Thomas, Jacob, Won, Thomas, Sandin, Anisa, Marmolejo, Sophia, Zeng, Andrew, Ito, Fumito, Kokot, Niels, Swanson, Mark, Kwon, Daniel, Tsao-Wei, Denice, Groshen, Susan, Kelly, Kevin, Martinez, Hugo Lara, Sherrod, Andy, Declerck, Brittney, Kim, Gene, Peng, David, Hu, Jenny C

“…BackgroundPD-1 blockade achieves response rates of ~50% in patients with unresectable or metastatic cutaneous squamous cell carcinoma (CSCC); furthermore,…”
Get full text

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study by Rohatgi, Nitin, Rothe, Michael, Mangat, Pam K, Garrett-Mayer, Elizabeth, Meric-Bernstam, Funda, Pisick, Evan, Alese, Olatunji B, Reynolds, Christopher M, Thota, Ramya, Vaccaro, Gina M, von Mehren, Margaret, Arend, Rebecca C, Chiu, Vi K, Duvivier, Herbert L, Gold, Philip J, Hack, Keely, Marr, Alissa S, Winer, Arthur, Grantham, Gina N, Hinshaw, Dominique C, Gregory, Abigail, Halabi, Susan, Schilsky, Richard L

“…The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating the antitumor activity of commercially available targeted…”
Get more information

A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study by Ernani, Vinicius, Jahan, Rahat, Smith, Lynette M., Marr, Alissa S., Kimbrough, Sarah E., Kos, Mary E., Tijerina, Jolene, Pivovar, Shannon, Lakshmanan, Imayavaramban, Ketcham, Marsha, Rauth, Sanchita, Mallya, Kavita, Nasser, Mohd W, Jain, Maneesh, Kessinger, Anne, Batra, Surinder K., Ganti, Apar Kishor

“…•Topotecan and doxorubicin provide sequential topoisomerase I and II inhibition.•Hematologic side effects were the most common. There were no therapy-related…”
Get full text

Advanced lung cancer in the older patient: is there a role for bevacizumab? by Marr, Alissa S, Ganti, Apar Kishor

Get full text

Weekly vinorelbine and paclitaxel in older patients with advanced non-small cell lung cancer: A phase II Fred and Pamela Buffet Cancer Center Clinical Trials Network study by Huerter, Mary M, Meza, Jane L, Copur, M. Sitki, Tolentino, Addison, Marr, Alissa S, Ketcham, Marsha, DeSpiegelaere, Holly, Kruse, Susan, Kos, Mary E, Swenson, Karin, Radniecki, Sarah E, Kessinger, Anne, Ganti, Apar Kishor

“…Abstract Objective Platinum-based doublet chemotherapy is the standard for most patients with advanced non-small cell lung cancer (NSCLC). Toxicity concerns…”
Get full text

A retrospective analysis of immune checkpoint inhibitors in patients with preexisting organ dysfunction by Kesireddy, Meghana, Marr, Alissa, Schissel, Makayla, Ganti, Apar K

“…There are limited to no data regarding the use of immune checkpoint inhibitors (ICIs) in patients who have preexisting organ dysfunction because these patients…”
Get full text

Immunotherapy-Induced Glomerulonephritis: Whodunit?: FR-PO201 by Benes, Brian, Muir, Kate-Lynn, Foster, Kirk W., Marr, Alissa S., Tendulkar, Ketki K.

Get full text

Phase I/II study to evaluate consolidative hypofractionated radiation therapy for boosting the residual primary disease in combination with durvalumab after definitive chemoradiation therapy for stage III non-small cell lung cancer (NSCLC): study protocol for a prospective trial by Coutu, Brendan, Lawrence, Elliot, Ganti, Apar Kishor, Marr, Alissa, Wichman, Chris, Zhang, Chi

“…Recent advancements in the management of non-small cell lung cancer (NSCLC) have confirmed the utility of adding adjuvant immunotherapy to concurrent…”
Get full text

Adjuvant Systemic Therapy in Patients With Early-Stage NSCLC Treated With Stereotactic Body Radiation Therapy by Ernani, Vinicius, Appiah, Adams Kusi, Marr, Alissa, Zhang, Chi, Zhen, Weining, Smith, Lynette M, Ganti, Apar Kishor

“…Stereotactic body radiation therapy (SBRT) is commonly used to treat nonsurgical patients with early-stage NSCLC. There are no prospective data on the role of…”
Get more information